Volume 7 Issue 1
Jan.  2016
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2016  >  7(1): 44-47
Wang Guoying, Tang Hui, Zhang Yingcai, et al. Programmed death receptor(PD)-1 monoclonal antibody-induced acute immune hepatitis in the treatment of recurrent hepatocellular carcinoma after liver transplantation: a case report[J]. ORGAN TRANSPLANTATION, 2016, 7(1): 44-47. doi: 10.3969/j.issn.1674-7445.2016.01.008
Citation: Wang Guoying, Tang Hui, Zhang Yingcai, et al. Programmed death receptor(PD)-1 monoclonal antibody-induced acute immune hepatitis in the treatment of recurrent hepatocellular carcinoma after liver transplantation: a case report[J]. ORGAN TRANSPLANTATION, 2016, 7(1): 44-47. doi: 10.3969/j.issn.1674-7445.2016.01.008
shu

Programmed death receptor(PD)-1 monoclonal antibody-induced acute immune hepatitis in the treatment of recurrent hepatocellular carcinoma after liver transplantation: a case report

doi: 10.3969/j.issn.1674-7445.2016.01.008

  • Department of Hepatic Surgery, Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University, Organ Transplantation Research Center of Guangdong Province, Transplantation Research Institute of Sun Yat-sen University, Guangzhou 510630, China

More Information
  • Corresponding author: Chen Guihua, Email: chgh1955@263.net
  • Received Date: 2015-10-16
    Available Online: 2021-01-19
  • Publish Date: 2016-01-15
    Abstract
  •   Objective  To explore the safety of programmed death receptor (PD)-1 monoclonal antibody for treatment of hepatocellular carcinoma (HCC) recurrence after liver transplantation.   Methods  Clinical data of 1 case with acute immune hepatitis induced by PD-1 monoclonal antibody(pembrolizumab) therapy for recurrent HCC after liver transplantation was retrospectively analyzed.   Results  The patient who received liver transplantation for primary HCC was diagnosed with lung metastasis at 4 months after the transplantation, and treated with the pembrolizumab (150 mg intravenous infusion of once) at 12 months after transplantation. Liver dysfunction was found at 5th d after treatment, and liver biopsy was conducted which showed pathological changes of mild to moderate acute rejection. It was diagnosed to be acute immune hepatitis based on the patient's clinical manifestations, laboratory examination and pembrolizumab drug instructions. After adrenal cortical hormone and intensive immunosuppressive therapy, the patient was followed up for 8 months, which showed that the patient survived with tumor, but the liver function remained abnormal.   Conclusions  PD-1 monoclonal antibody and other immune checkpoint inhibitors are not suitable for the immunologic suppression after liver transplantation due to the risk of inducing immune hepatitis.

     

    • FullText(HTML)
  • loading
    • References(15)
  • [1]
    Couzin-Frankel J. Breakthrough of the year 2013. cancer immunotherapy[J]. Science,2013,342(6165):1432-1433. doi: 10.1126/science.342.6165.1432
    [2]
    Lee JH, Lee JH, Lim YS, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma[J]. Gastroenterology,2015,148(7):1383-1391. doi: 10.1053/j.gastro.2015.02.055
    [3]
    Hato T, Goyal L, Greten TF, et al. Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions[J]. Hepatology,2014,60(5):1776-1782. doi: 10.1002/hep.v60.5
    [4]
    Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation[J]. J Exp Med,2000,192(7):1027-1034. doi: 10.1084/jem.192.7.1027
    [5]
    Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation[J]. Nat Immunol,2001,2(3):261-268. doi: 10.1038/85330
    [6]
    Brown JA, Dorfman DM, Ma FR, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production[J]. J Immunol,2003,170(3):1257-1266. doi: 10.4049/jimmunol.170.3.1257
    [7]
    Dong H, Chen L. B7-H1 pathway and its role in the evasion of tumor immunity[J]. J Mol Med,2003,81(5):281-287. http://cn.bing.com/academic/profile?id=1870078228&encoded=0&v=paper_preview&mkt=zh-cn
    [8]
    Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade[J]. Proc Natl Acad Sci U S A,2002,99(19):12293-12297. doi: 10.1073/pnas.192461099
    [9]
    Sawada Y, Yoshikawa T, Shimomura M, et al. Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes[J]. Int J Oncol,2015,46(1):28-36. http://cn.bing.com/academic/profile?id=2038159871&encoded=0&v=paper_preview&mkt=zh-cn
    [10]
    Gao Q, Wang XY, Qiu SJ, et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma[J]. Clin Cancer Res,2009,15(3):971-979. doi: 10.1158/1078-0432.CCR-08-1608
    [11]
    Umemoto Y, Okano S, Matsumoto Y, et al. Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy[J]. J Gastroenterol,2015,50(1):65-75. doi: 10.1007/s00535-014-0933-3
    [12]
    Gehring AJ, Ho ZZ, Tan AT, et al. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma[J]. Gastroenterology,2009,137(2):682-690. doi: 10.1053/j.gastro.2009.04.045
    [13]
    Ozkaynak E, Wang L, Goodearl A, et al. Programmed death-1 targeting can promote allograft survival[J].J Immunol,2002,169(11):6546-6553. doi: 10.4049/jimmunol.169.11.6546
    [14]
    Cao Y, Zhou H, Tao J, et al. Keratinocytes induce local tolerance to skin graft by activating interleukin-10-secreting T cells in the context of costimulation molecule B7-H1[J]. Transplantation,2003,75(8):1390-1396. doi: 10.1097/01.TP.0000061599.24682.EC
    [15]
    Merck Sharp & Dohme Corporation. Prescribing information for KEYTUDA[EB/OL].[2015-10-05]. http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (311) PDF downloads(96) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return